Abstract
To test the efficacy of sertraline in the treatment of night eating syndrome. Seventeen patients meeting criteria for night eating syndrome received sertraline in a 12-week open-label, nonblind trial. Outcome was assessed by four primary measures, namely, the number of nocturnal awakenings, the number of ingestions, total daily caloric intake after the evening meal, and an overall rating of change from the Clinical Global Impression of Improvement scale (CGI-I). An intent-to-treat analysis revealed highly significant improvements across all four primary outcome measures for all 17 subjects. Five subjects achieved full remission of symptoms (CGI-I score of 1 = very much improved) and lost a significant amount of weight over the course of the study (-4.8 +/- 2.6 kg, p < .05). Sertraline, a selective serotonin reuptake inhibitor, may be beneficial in the treatment of night eating syndrome.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
